Most Popular
-
1
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
2
First snow to fall in Seoul on Wednesday
-
3
S. Korea not to attend Sado mine memorial: foreign ministry
-
4
Man convicted after binge eating to avoid military service
-
5
Wealthy parents ditch Korean passports to get kids into international school
-
6
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
7
Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
-
8
[Weekender] Korea's traditional sauce culture gains global recognition
![[Weekender] Korea's traditional sauce culture gains global recognition](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
-
9
BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
-
10
Korea to hold own memorial for forced labor victims, boycotting Japan’s
![[Weekender] Korea's traditional sauce culture gains global recognition](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
[THE INVESTOR] Alpha Holdings announced on Oct. 13 that it has acquire additional stake in the US-based immunity anti-cancer medicine firm Viral Gene.
Including the stake held by its subsidiary Alpha Biolabs, Alpha Holding’s is now the US-based company’s largest shareholder with 37.64 percent stake.
Alpha Holdings acquired Viral Gene shares held by TJU Asset Management and Penn Life Science, which each acquired 1.66 percent of its shares.
Viral Gene is currently developing a treatment for colorectal cancer, and plans to begin phase 2 clinical trials within the year.
By Choi He-suk (cheesuk@heraldcorp.com)
Including the stake held by its subsidiary Alpha Biolabs, Alpha Holding’s is now the US-based company’s largest shareholder with 37.64 percent stake.
Alpha Holdings acquired Viral Gene shares held by TJU Asset Management and Penn Life Science, which each acquired 1.66 percent of its shares.
Viral Gene is currently developing a treatment for colorectal cancer, and plans to begin phase 2 clinical trials within the year.
By Choi He-suk (cheesuk@heraldcorp.com)
![[More than APT] Residents, architects together design homes](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/11/24/20241124050036_0.jpg&u=)
